Since CRC tumors with KRAS and BRAF wild type are expected to respond to anti-EGFR therapies, we took advantage of the human CRC cell CACO-2 exhibiting wild type KRAS and BRAF. HT-29 and DLD-1 served as negative controls being positively screened for an activating BRAF or KRAS mutation, respectively. This evidence concerns the gene BRAF and colorectal carcinoma.